FCN1

FCN1 encodes Ficolin-1 (M-ficolin), a soluble collagen-like pattern recognition receptor that binds acetylated compounds and sugar structures on microorganisms and apoptotic cells via its fibrinogen-like domain, thereby initiating the lectin complement pathway (PMID:19501910). Non-synonymous mutations such as Ala218Thr and Asn289Ser impair ligand binding to pathogens like Group B Streptococcus, while Ser268Pro abolishes protein production entirely (PMID:23209787). Beyond complement activation, the collagen-like domain of Ficolin-1 directly interacts with the CH1/CH3 regions of IgG1, and in macrophages FCN1 promotes LPS-induced IL-1β maturation through the NLRP3–caspase-1 inflammasome axis (PMID:28900133, PMID:36932401).

1. 2009 High

   Establishing FCN1 as a pattern recognition molecule that activates the lectin complement pathway resolved the fundamental question of how this collagen-like lectin contributes to innate immunity.

   Evidence Synthesis of binding and complement activation assays from multiple laboratories

   PMID:19501910

   Open questions at the time

   • Structural basis for ligand selectivity of the fibrinogen-like domain not resolved
   • Relative contribution of FCN1 versus other ficolins to complement activation in vivo unclear
2. 2012 Medium

   Demonstration that promoter polymorphisms at -542 and -144 regulate FCN1 transcription and protein secretion in monocytes established that genetic variation controls Ficolin-1 availability at the expression level.

   Evidence Allele-specific mRNA quantification, ELISA of monocyte supernatants, and plasma Ficolin-1 measurement in genotyped individuals

   PMID:22673311

   Open questions at the time

   • Transcription factor(s) binding at -542/-144 not identified
   • Functional consequences of reduced Ficolin-1 levels on complement activation not measured
3. 2012 High

   Identification of non-synonymous FCN1 mutations that impair ligand binding or abolish protein production demonstrated that coding-region variants directly compromise Ficolin-1 function at the protein level.

   Evidence Recombinant mutagenesis, Group B Streptococcus binding assays, and genotype–phenotype correlation in 346 blood donors

   PMID:23209787

   Open questions at the time

   • Structural mechanism by which Ala218Thr and Asn289Ser reduce binding affinity not determined
   • Clinical disease associations of these variants not established in prospective cohorts
4. 2017 Medium

   Mapping a direct interaction between the collagen-like domain of Ficolin-1 and IgG1 CH1/CH3 regions revealed an unexpected link between the lectin pathway and adaptive humoral immunity.

   Evidence In vitro Western blot co-binding assays, recombinant domain mapping, and synthetic peptide inhibition

   PMID:28900133

   Open questions at the time

   • Physiological relevance of the FCN1–IgG1 interaction (e.g., opsonization enhancement, immune complex clearance) not demonstrated in vivo
   • Binding affinity and stoichiometry not quantified by biophysical methods
5. 2023 Medium

   Showing that FCN1 overexpression promotes LPS-induced IL-1β maturation via the NLRP3–caspase-1 axis placed Ficolin-1 upstream of inflammasome activation, expanding its role beyond complement to macrophage inflammatory signaling.

   Evidence FCN1 overexpression in THP-1-derived macrophages with LPS stimulation; Western blot and qRT-PCR for NLRP3 pathway components

   PMID:36932401

   Open questions at the time

   • Mechanism by which FCN1 activates NLRP3 (direct interaction vs. upstream signaling intermediate) not identified
   • Loss-of-function validation (knockout/knockdown) not reported
   • Relevance confirmed only in a single cell line model

• The direct molecular mechanism linking Ficolin-1 to NLRP3 inflammasome assembly, the physiological significance of the FCN1–IgG1 interaction in vivo, and the structural basis for ligand discrimination by the fibrinogen-like domain remain unresolved.
• No structural model of Ficolin-1 fibrinogen-like domain bound to a natural ligand
• In vivo loss-of-function models for FCN1 not reported in the literature
• Whether FCN1–IgG1 binding modulates adaptive immune responses is untested